WELCOME

This website has not been updated for some time. However, links to PDFs of publications until 2008 are available under the the Publications tab.

For a more upto date version please visit http://www.jayantvaidya.org/

Professor Jayant Vaidya is a breast cancer expert who specialises in the diagnosis and treatment of diseases of the breast. He is a Consultant Surgeon at the Whittington, Royal Free and University College London Hospitals. His private breast practice is at the London Breast Institute at the Princess Grace Hospital, where he runs a One Stop breast clinic and sees emergency cases.

He is extremely active in many research projects for breast disease and breast cancer. With his PhD thesis at University College London, he pioneered the concept of targeted intraoperative radiotherapy (TARGIT or IORT), to deliver radiotherapy to women at the time of surgery as opposed to the usual 6-week course of post-operative radiotherapy. He has been featured on BBC’s Tomorrow’s World in relation to this.

He qualified in surgical oncology (MBBS MS DNB) from the Bombay University and the National Board. His PhD is from London University and he is a Fellow of the Royal College of Surgeons, FRCS, UK. At the age of 17 he was declared a National Scholar and received a scholarship throughout his medical education.

He has worked at the Tata Memorial Hospital, Royal Marsden Hospital, University College London and the University of Dundee, and is currently Professor of Surgery and Oncology at University College London

Clinical Practice

His clinical practice has been busy. He has long experience in all aspects of breast surgery including lumpectomy, wide local excision and quadrantectomy for breast cancer along with glanduloplasty; sentinel node biopsy / axillary sampling, axillary clearance, and targeted intraoperative radiotherapy. He manages women with familial breast cancer and worried well and women at high risk of developing breast cancer. He works in conjunction with renowned plastic surgeons for breast reconstructive surgery. He is well versed with multidisciplinary approach to breast cancer treatment and works very closely with a renowned team of medical oncologists, radiotherapists, radiologists and pathologists, as well as specialists in psychosocial care.

Research Interests

Mr Vaidya is considered a world opinion leader in breast cancer. He has over 200 original publications on varied subjects, and has given over 150 invited talks, including the European Breast Cancer Conference (EBCC), European Cancer Conference (ECCO), Milan breast cancer conference and the San Antonio breast cancer conference, American Society of Breast Surgeons, American Society of Clinical Oncology Breast symposium, American Brachytherapy Society. He has been invited to contribute to several books on breast cancer. Fifth edition of his book “Fast Facts – breast cancer” is due to to published in 2014. He has also featured in Time Magazine and Reader's Digest.

His main research interest is understanding the natural history of breast cancer and how to treat it with maximum effectiveness and minimal harm. His work on IORT was inspired by his original laboratory work in 1994-5, that led him to the idea that breast cancer treatment with surgery and radiotherapy needs to be focussed and targeted. Working with Professor Michael Baum and Professor Jeffrey Tobias, he developed the concept, tools and the surgical operative procedure to give targeted intraoperative radiotherapy to the tissues immediately around a breast cancer, after it is surgically removed. He called it TARGIT- for TARGeted Intraoperative radioTherapy.

The TARGIT procedure has been now been used in over 8000 women worldwide. Given as a tumour bed boost, TARGIT appears to achieve more than 98% durable local control, a remarkable result. The results of the international TARGIT-A trial in 33 centres specialist cancer centres worldwide accrured patients from 2000-2012. His recent collaoborative translational research work suggests that TARGIT treatment may also change the tumour micro-environment making it less conducive for tumour growth. The TARGIT-A trial results found that a single dose of radiotherapy, given in the operation theatre, immediately after removal of the breast cancer results in noninferior cancer control to the standard 6-week course of postoperative radiotherapy; furthermore, there were fewer deaths from causes other than breast cancer with TARGIT. The TARGIT-B trial will inform us whether TARGIT boost is superior to the standard postoperative boost because it is accurately timed and targeted. To read more about his publications, please browse this website and for literature about the TARGIT trial, go to www.targit.org.uk

Contact details

NHS: Department of Surgery, Whittington Hospital NHS Trust, Magdala Avenue, London N19 5NF. Tel: 0207 288 5831

Academic: Research Department of Surgery, 2nd Floor, Clerkenwell Building, University College London, Highgate Hill, London N19 5LW Tel: 0207 288 3970 or 0207 288 5831

Private patients: The Harley Street Clinic, 79 Harley Street, London W1G 8PX. Tel: 0207 034 8890

Selected and Recent publications

Papers and Presentations related to TARGeted Intraoperative radioTherapy (TARGIT)